Granite Point Capital Management, L.P. Cassava Sciences Inc Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
A detailed history of Granite Point Capital Management, L.P. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Granite Point Capital Management, L.P. holds 612,000 shares of SAVA stock, worth $1.27 Million. This represents 2.91% of its overall portfolio holdings.
Number of Shares
612,000Holding current value
$1.27 Million% of portfolio
2.91%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding SAVA
# of Institutions
131Shares Held
14.2MCall Options Held
962KPut Options Held
864K-
Black Rock Inc. New York, NY3.22MShares$6.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.17MShares$4.51 Million0.0% of portfolio
-
David A. Siegel Two Sigma Advisers, LP | New York, Ny984KShares$2.05 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY790KShares$1.64 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY613KShares$1.28 Million0.0% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $83.4M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...